Home / Intelligence / Webinars / Elevating Commercialization in China Part 1: The Path to Launch
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, sales for innovative drugs in China are often only a fraction of those in the U.S. The complex and rapidly evolving market dynamics require companies to stay on the cutting edge of new regulatory pathways, pricing/market access and go-to-market models.
Join Trinity Life Sciences’ APAC experts as they explore the key dynamics of the pharmaceutical market in China and uncover multiple strategies and levers that can elevate commercial success in this market.
In this three-part webinar series, our experts will explore:
Part 1: The Path to Launch | Available On Demand
Leveraging novel commercialization pathways for innovative therapies
Part 2: The Key to Pricing & Access Optimization | October 18th or 19th
Decoding the current dynamics and future trends of Pricing and Market Access
Part 3: The Winning Commercial Model | Upcoming
Building a model to match China’s changing dynamics
Key Topics Covered In Part 1:
- Regulatory pathways to accelerate commercial launch in China
- Balancing pros and cons
- Insights from recent launches
Featuring
Andy Wong
Partner,
Strategic Advisory
Tony Xu
Associate Principal,
Strategic Advisory
Yitong Li
Senior Consultant & APAC Expert,
Strategic Advisory
Complete the form below to view the on-demand webinar:
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the […]
Read More